Search results for "Platelet Count"

showing 10 items of 66 documents

Sudden sensorineural hearing loss: is there a relationship between routine haematological parameters and audiogram shapes?

2016

Objective: To investigate the relationship between haematological routine parameters and audiogram shapes in patients affected by sudden sensorineural hearing loss (SSNHL). Design: A retrospective study. All patients were divided into four groups according to the audiometric curve and mean values of haematological parameters (haemoglobin, white blood cell, neutrophils and lymphocytes relative count, platelet count, haematocrit, prothrombin time, activated partial thromboplastin time, fibrinogen and neutrophil-to-lymphocite ratio) of each group were statistically compared. The prognostic role of blood profile and coagulation test was also examined. Study sample: A cohort of 183 SSNHL patient…

MaleTime FactorsNeutrophilshaematological parameterAudiologyLanguage and LinguisticsHemoglobinsLeukocyte Count0302 clinical medicineHearingLymphocytes030223 otorhinolaryngologyHematologic Testsmedicine.diagnostic_testComplete blood countAudiogramSudden sensorineural hearing lossMiddle AgedSettore MED/32 - AudiologiaTreatment OutcomeSettore MED/31 - Otorinolaringoiatriamedicine.anatomical_structureHematocrit030220 oncology & carcinogenesisCohortAudiometry Pure-ToneFemalePartial Thromboplastin TimeSteroidsmedicine.symptomPartial thromboplastin timeAdultBlood PlateletsLinguistics and Languagemedicine.medical_specialtyHearing lossHearing Loss Sensorineural03 medical and health sciencesSpeech and HearingAudiogram shapePredictive Value of TestsWhite blood cellmedicineHumansBlood CoagulationRetrospective StudiesProthrombin timePlatelet Countbusiness.industryFibrinogenAuditory ThresholdRetrospective cohort studyRecovery of FunctionHearing Loss Suddenaudiogram shape; haematological parameters; Sudden sensorineural hearing lossProthrombin TimebusinessBiomarkersInternational Journal of Audiology
researchProduct

Two new cases of Thrombocytopenia Absent Radius (TAR) syndrome: Clinical, Genetic and Nosologic Features

1988

Two unrelated children affected by TAR syndrome, autosomic recessive disease with congenital thrombocytopenia and bilateral radial aplasia, are described. In the first case a mild thrombocytopenia has been compatible with a fairly normal life until the second year of age. The other child shows radial aplasia associated with other anomalies of the upper limbs, severe thrombocytopenia and leukemoid reaction. The relationship among TAR syndrome, Fanconi's anemia and Roberts' syndrome are briefly discussed.

Malecongenital hereditary and neonatal diseases and abnormalitiesPathologymedicine.medical_specialtyEctromeliaAnemiaChromosome DisordersGenes RecessiveRadial aplasiaBiologyConsanguinityBilateral radial aplasiahemic and lymphatic diseasesmedicineClinical geneticHumansAbnormalities MultipleChromosome AberrationsPlatelet CountTAR syndromeInfantSyndromemedicine.diseaseThrombocytopeniaDermatologySevere thrombocytopeniaRadiusPediatrics Perinatology and Child HealthFemaleAbsent radiusLeukemoid reactionKlinische Pädiatrie
researchProduct

A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Pati…

2020

INTRODUCTION Metabolic-associated fatty liver disease is common, with fibrosis the major determinant of adverse outcomes. Population-based screening tools with high diagnostic accuracy for the staging of fibrosis are lacking. METHODS Three independent cohorts, 2 with both liver biopsy and liver stiffness measurements (LSMs, n = 254 and 65) and a population sample (n = 713), were studied. The performance of a recently developed noninvasive algorithm (ADAPT [age, diabetes, PRO-C3 and platelets panel]) as well as aspartate aminotransferase-to-platelet ratio index, fibrosis-4, nonalcoholic fatty liver disease fibrosis score, and LSM was used to stage patients for significant (≥F2) and advanced …

Malemedicine.medical_specialtyBiopsyPopulationGastroenterology03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseasePredictive Value of TestsDiabetes mellitusInternal medicineNonalcoholic fatty liver diseasemedicineDiabetes MellitusHumansAspartate Aminotransferaseseducationeducation.field_of_studyHepatologymedicine.diagnostic_testReceiver operating characteristicbusiness.industryPlatelet CountFatty liverGastroenterologyAge FactorsOdds ratioMiddle Agedmedicine.diseaseCollagen Type III030220 oncology & carcinogenesisLiver biopsyElasticity Imaging Techniques030211 gastroenterology & hepatologyFemalebusinessAlgorithmsBiomarkersThe American journal of gastroenterology
researchProduct

Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility

2020

Abstract Background The Sars-CoV-2 can cause severe pneumonia with multiorgan disease; thus, the identification of clinical and laboratory predictors of the progression towards severe and fatal forms of this illness is needed. Here, we retrospectively evaluated and integrated laboratory parameters of 45 elderly subjects from a long-term care facility with Sars-CoV-2 outbreak and spread, to identify potential common patterns of systemic response able to better stratify patients’ clinical course and outcome. Methods Baseline white blood cells, granulocytes’, lymphocytes’, and platelets’ counts, hemoglobin, total iron, ferritin, D-dimer, and interleukin-6 concentration were used to generate a …

Malemedicine.medical_specialtyLymphocyteIronlcsh:MedicineDiseaseMonocyteGeneral Biochemistry Genetics and Molecular BiologyMonocytesFibrin Fibrinogen Degradation ProductsLeukocyte CountLong-term care facilitieInternal medicineD-dimermedicineHumansLymphocytesAgedRetrospective StudiesAged 80 and overbiologybusiness.industryPlatelet CountLong-term care facilitiesClinical outcomeSARS-CoV-2MonocyteResearchlcsh:RCOVID-19Retrospective cohort studyGeneral MedicineBiomarkerMiddle Agedmedicine.diseasePrognosisLong-Term CareFerritinPneumoniamedicine.anatomical_structureTreatment OutcomeD-dimerbiology.proteinFemaleLymphocyteHemoglobinbusinessBiomarkers
researchProduct

Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hor…

2012

OBJECTIVE: An increased prevalence of hematological abnormalities is reported in acromegaly, but to date no reports about the presence of the Janus Kinase (JAK) 2 mutation in acromegalic patients have been described. DESIGN: We report the complex clinical presentation of the unique case, never described, of acromegaly due to GH-secreting pituitary adenoma associated with JAK2 V617F mutation. RESULTS: The patient shows primary thrombocythemia and myelofibrosis, due to JAK2 V617F mutation, severe visceromegaly and a peculiar clinical course of the disease characterized by discrepant values of GH and IGF-1 during somatostatin analog (SA) treatment despite a significant reduction in pituitary a…

Malemedicine.medical_specialtyTime FactorsEndocrinology Diabetes and MetabolismGrowth hormone receptorAcromegaly HGH IGF-1GastroenterologySettore MED/13 - EndocrinologiaCohort StudiesEndocrinologyPituitary adenomahemic and lymphatic diseasesInternal medicineAcromegalymedicineAnimalsHumansPituitary NeoplasmsInsulin-Like Growth Factor IRadiometryMyelofibrosisAgedJanus kinase 2biologyHuman Growth HormonePlatelet Countbusiness.industryJanus Kinase 2medicine.diseaseAcromegaly Growth hormone Insulin-like growth factor-1 Janus kinase 2 Growth hormone receptorEndocrinologyAcromegalyMutationPegvisomantbiology.proteinJanus kinasebusinessVisceromegalyFollow-Up StudiesThrombocythemia Essentialmedicine.drug
researchProduct

Splenic marginal zone lymphoma: A prognostic model for clinical use

2006

The Integruppo Italiano Linfomi (IIL) carried out a study to assess the outcomes of splenic marginal zone lymphoma and to identify prognostic factors in 309 patients. The 5-year cause-specific survival (CSS) rate was 76%. In univariate analysis, the parameters predictive of shorter CSS were hemoglobin levels below 12 g/dL (P < .001), albumin levels below 3.5 g/dL (P = .001), International Prognostic Index (IPI) scores of 2 to 3 (P < .001), lactate dehydrogenase (LDH) levels above normal (P < .001), age older than 60 years (P = .01), platelet counts below 100 000/μL (P = .04), HbsAg-positivity (P = .01), and no splenectomy at diagnosis (P = .006). Values that maintained a negative influence …

Malesplenic marginal zone lymphoma; prognostic factors; International Prognostic Index (IPI)VILLOUS LYMPHOCYTESHydro-LyaseB-CELLLongitudinal StudiePredictive Value of TestInternational Prognostic Index (IPI)BiochemistryGastroenterologyHemoglobinschemistry.chemical_compoundInternational Prognostic IndexRisk FactorsBONE-MARROW INFILTRATION; NON-HODGKINS-LYMPHOMA; C VIRUS-INFECTION; VILLOUS LYMPHOCYTES; B-CELLBONE-MARROW INFILTRATIONAge FactorLongitudinal StudiesMultivariate AnalysiAged 80 and overUnivariate analysisHematologyMortality rateAge FactorsHematologyMiddle AgedPrognosisSplenic NeoplasmSurvival RatePredictive value of testsHumanAdultmedicine.medical_specialtyLymphoma B-CellPrognosiImmunologysplenic marginal zone lymphomaDisease-Free SurvivalPredictive Value of TestsAlbuminsInternal medicineLactate dehydrogenaseAdult; Age Factors; Aged; Aged 80 and over; Albumins; Disease-Free Survival; Hemoglobins; Humans; Hydro-Lyases; Longitudinal Studies; Lymphoma B-Cell; Male; Middle Aged; Multivariate Analysis; Platelet Count; Predictive Value of Tests; Prognosis; Risk Factors; Splenic Neoplasms; Survival Rate; Models Theoretical; HematologymedicineHumansHemoglobinNON-HODGKINS-LYMPHOMASplenic marginal zone lymphomaSurvival rateHydro-LyasesAgedPlatelet Countbusiness.industrySplenic NeoplasmsAlbuminRisk Factorprognostic factorsCell BiologyModels Theoreticalmedicine.diseaseSurgerychemistryMultivariate AnalysisbusinessC VIRUS-INFECTION
researchProduct

A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma

2006

Potential synergistic interaction between gemcitabine (GEM) and epirubicin (EPI) in pancreatic cancer have been described previously. The maximum-tolerated dose in this trial was GEM 1000 mg m(-2) and EPI 45 mg m(-2). Median time to progression was 5.1 months and median survival time 7.4 months. This combination appears well tolerated and shows promising clinical activity.

OncologyAdultMaleCancer Researchmedicine.medical_specialtyPancreatic diseaseendocrine system diseasesmedicine.drug_classmedicine.medical_treatmentpancreatic cancerAntineoplastic AgentschemotherapyAntimetaboliteDeoxycytidinechemistry.chemical_compoundHemoglobinsLeukocyte CountInternal medicinePancreatic cancerClinical StudiesmedicineHumansIn patientAgedNeoplasm StagingChemotherapyDose-Response Relationship Drugbusiness.industryPlatelet CountgemcitabineMiddle Agedmedicine.diseaseepirubicinGemcitabineSurgeryPancreatic NeoplasmsOncologychemistryDeoxycytidineFemalebusinessEpirubicinmedicine.drugBritish Journal of Cancer
researchProduct

Extreme thrombocytosis as a sign of coeliac disease in the elderly: case report

2002

Increase in the number of blood platelets to over 1 000 000/mm 3 in elderly patients is generally considered secondary to a myeloproliferative or neoplastic disease. To report the case of an elderly woman hospitalized for extreme thrombocytosis associated with severe anaemia, who was found to be suffering from coeliac disease. The patient, aged 83 years, was hospitalized presenting with fatigue. Laboratory tests showed microcytic hypochromic anaemia (haemoglobin 4 g/dl) and extreme thrombocytosis (platelet count 1 400 000/mm 3 ). Physical examination was normal, with the exception of marked thinness. There was no evidence of macroscopic bleeding from the gastrointestinal or genitourinary tr…

Pathologymedicine.medical_specialtySettore MED/09 - Medicina InternaAtrophic gastritisPhysical examinationRisk AssessmentSeverity of Illness IndexCoeliac diseaseDiagnosis DifferentialHumanscoeliac disease thrombocytosis iron-deficiency anaemia elderlyMedicineIntestinal MucosaAgedAged 80 and overThrombocytosisLamina propriaHepatologymedicine.diagnostic_testThrombocytosisPlatelet Countbusiness.industryGastroenterologyPrognosismedicine.diseaseCeliac Diseasemedicine.anatomical_structureIron-deficiency anemiaSerum ironAbdomenFemalebusinessEuropean Journal of Gastroenterology &amp; Hepatology
researchProduct

Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report

2021

Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by isolated thrombocytopenia (platelet count &lt;100 × 109/l) in the absence of other causes or disorders associated. The incidence of ITP in pregnancy is one to two cases per 1000 gestations. ITP could be diagnosed before or during pregnancy; sometimes a relapse of a previously diagnosed ITP can occur. Intravenous immune globulins (IVIg) and corticosteroids are the standard frontline therapy because of their well known safety profile either for the mother or for the neonate. Treatments for refractory patients are limited by potential fetal risk. We report the case of a patient with ITP along pregnancy, refractory…

Pediatricsmedicine.medical_specialtyAdolescenteltrombopag pregnancy.EltrombopagBenzoateschemistry.chemical_compoundRefractoryPregnancyhemic and lymphatic diseasesMedicineHumansThrombopoietin receptorFetusPregnancyPurpura Thrombocytopenic Idiopathicbusiness.industryPlatelet CountIncidence (epidemiology)Pregnancy Complications HematologicInfant NewbornHematologyGeneral Medicinemedicine.diseaseHydrazineschemistryGestationPyrazolesFemalebusinessComplicationReceptors ThrombopoietinPrimary immune thrombocytopenia
researchProduct

Modification of xenogenic bone substitute materials - effects on the early healing cascadein vitro

2013

Introduction Initial platelet activation with subsequent cytokine release at the defect site plays a crucial role in tissue integration. The aim of this study was to evaluate the influence of topographic and biomimetic collagen modifications of a xenogenic bone substitute material (BSM) on in vitro platelet activation and cytokine release. Material and Methods Three types of xenogenic BSM were used. Two BSM with different levels of granularity (large granule BSM [XBSM/L], small granule BSM [XBSM/S]) and a BSM with collagen (XBSM/C). All three samples were incubated with platelet concentrate of four healthy volunteers at room temperature for 15 min. For all groups, highly thrombogenic collag…

Vascular Endothelial Growth Factor Amedicine.medical_specialtymedicine.medical_treatmentEnzyme-Linked Immunosorbent AssayIn Vitro TechniquesBiomimetic MaterialsTransforming Growth Factor betaIn vivoInternal medicinemedicineHumansPlateletPlatelet activationBone regenerationPlatelet-Derived Growth FactorMineralsWound HealingbiologyPlatelet CountChemistryPlatelet ActivationIn vitroInsulin-Like Growth Factor Binding Protein 1CytokineEndocrinologyBone SubstitutesImmunologybiology.proteinCytokinesCollagenOral SurgeryWound healingPlatelet-derived growth factor receptorClinical Oral Implants Research
researchProduct